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The conserved hemagglutinin (HA) stem has been a focus of universal influenza vaccine
efforts. Influenza A group 1 HA stem-nanoparticles have been demonstrated to confer het-
erosubtypic protection in animals; however, the protection does not extend to group 2
viruses, due in part to differences in glycosylation between group 1 and 2 stems. Here, we
show that introducing the group 2 glycan at Asn38HA1 to a group 1 stem-nanoparticle (gN38
variant) based on A/New Caledonia/20/99 (H1N1) broadens antibody responses to cross-
react with group 2 HAs. Immunoglobulins elicited by the gN38 variant provide complete
protection against group 2 H7N9 virus infection, while the variant loses protection against a
group 1 H5N1 virus. The N38HA1 glycan thus is pivotal in directing antibody responses by
controlling access to group-determining stem epitopes. Precise targeting of stem-directed
antibody responses to the site of vulnerability by glycan repositioning may be a step towards
achieving cross-group influenza protection.
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Influenza virus is a rapidly-evolving pathogen that continues topose a substantial public health burden worldwide despite theavailability of licensed vaccines, underscoring the need for
more efficacious vaccines. Hemagglutinin (HA) is the most pre-
valent influenza viral surface glycoprotein and engages sialic acid
moieties on host cell surface to mediate viral attachment,
virus–host membrane fusion and infection1,2. Thus, HA is a
primary target for neutralizing antibodies and vaccine design.
Based on phylogenetic analysis, influenza A virus HAs can be
divided into 18 subtypes (H1–H18) and classified as either group
1 or group 2 (refs. 3,4). Since antibodies that cross-react to mul-
tiple HA subtypes within a group and/or across groups are of
great interest for universal influenza vaccine efforts5,6, numerous
studies to elucidate the molecular and structural basis for
antibody-mediated neutralization have been reported in the past
few decades (reviewed in refs. 7–9). These studies provide the
rationale for building vaccines to focus on the conserved antigenic
supersites of the virus that are recurrently targeted by broadly
neutralizing antibodies (bNAbs) in multiple individuals.
Current influenza vaccines provide protection primarily
through the induction of neutralizing antibodies against the
immunodominant globular head region of the HA which
undergoes continuous antigenic drift, and hence, is highly vari-
able among different isolates. As a result, current seasonal vac-
cines are effective only against antigenically-matched viruses and
minimally protective against antigenically mismatched viruses or
pandemic strains. In contrast, the immunologically subdominant
stem region of HA is highly conserved among and across sub-
types and targeted by a number of bNAbs capable of cross-
reacting with multiple viral subtypes10–22. Thus, directing
vaccine-induced antibody responses to the conserved stem region
has been a major strategy for universal influenza vaccine devel-
opment efforts23–28.
To date, several studies have shown that engineered HA stem-
based immunogens that lack the immunodominant globular head
domain conferred protection against heterosubtypic influenza
virus infections in animal models26,29–34. One such vaccine that
displays the structurally stabilized group 1 HA stem trimers on
self-assembling nanoparticles conferred antibody-mediated het-
erosubtypic H5N1 protection in mice and ferrets32. However, the
molecular properties of HA stem immunogens required to confer
protection across groups has not been fully elucidated. In the last
decade, a number of HA stem-directed human bNAbs have been
discovered and structurally characterized10–14,18,20–22, providing
deeper structural understanding of antibody recognition of the
HA stem supersite. Although several exceptional bNAbs recog-
nize and neutralize viruses across groups, many other bNAbs only
neutralize viruses across subtypes within either group 1 or 2.
Differences in glycosylation sites on the HA stem between group
1 and 2 have been suggested to have a major impact on acces-
sibility of the stem epitope and may pose a substantial hurdle to
eliciting antibodies with cross-group reactivity22,35. Although
most group 1 HAs possess an N-linked glycosylation site at
N33HA1, most group 2 HAs have a glycan at N38HA1 with the
exception of H4 and H14 subtypes. Importantly, some of the
most prevalent human HA stem-directed antibodies that broadly
recognize group 1 HAs such as those derived from the VH1-69
lineage12,14–16,36–38 generally do not tolerate the group 2 glycan
attached to N38HA1 as the location of this glycan overlaps with
the epitope. While this group 2 glycan at N38HA1 poses a major
challenge for group 1-restricted bNAbs to gain cross-reactivity to
group 2 HAs, its role in eliciting cross-group antibody responses
and shaping antibody specificity are not fully understood.
In this study, we either introduce the group 2-like N-linked
glycosylation site at the position 38HA1 on the group 1 HA stem
nanoparticle based on A/New Caledonia/20/99 (H1N1) (NC99)
or replace the parental His residue at 38HA1 with a bulkier Arg,
and then assess antigenic and immunological consequences of
these changes. These variant nanoparticles are characterized
for their recognition by group 1-, group 2- and cross-group
stem-directed bNAbs. The specificity of antibody responses and
protective immune responses elicited by the variant stem nano-
particles to homologous H1N1 NC99, heterosubtypic group 1
H5N1 and group 2 H7N9 viruses are also assessed. Collectively,
these modifications to position 38HA1 substantially alter both the
antigenicity and immunogenicity profile of group 1 stem nano-
particles. Access of group 1-specific bNAbs to the HA stem
supersite is abrogated, while access of cross-group bNAbs is not
impeded, which results in the elicitation of antibodies that
recognize group 2 HA in immunized mice. Furthermore,
immunoglobulins (Igs) purified from mice immunized with
group 2 glycan variant nanoparticle provide complete protection
against H7N9 infection in mice when the Igs are passively
administered, suggesting that the position 38HA1 modification
may be a pivotal step for achieving cross-group influenza
protection.
Results
Characterization of group 1 H1 stem nanoparticle variants.
Most influenza A HAs possess 3 or 4 potential N-linked glyco-
sylation sites on the stem region of each protomer. While the
locations of these glycans are generally conserved among different
subtypes within each group, one of the glycosylation sites is
noticeably different between group 1 and group 2 HAs (N33HA1
and N38HA1, respectively) (Fig. 1a). The group 2 glycan at
N38HA1 is located within the canonical group 1-specific stem
bNAb epitope exemplified by CR6261 (refs. 12,15) (Fig. 1a). To
empirically test the impact of this group 2 glycan at N38HA1 in
the context of group 1 stem, we altered a group 1 H1 stem
nanoparticle (H1ssF) based on A/New Caledonia/20/1999
(NC99)32 with two point mutations (H38N and V40T in HA1,
H3 numbering39) to introduce the group 2-like N-linked glyco-
sylation sequon (H1ssF gN38) (Fig. 1b). In addition, we also
made a variant H1ssF possessing Arg at 38HA1 (H1ssF R38) to
test whether replacing the wild-type (WT) His with a larger side
chain (H38R in HA1) alters the antigenicity and immunogenicity
of the group 1 stem (Fig. 1b). The H1ssF and its gN38 and R38
variant nanoparticles were produced in mammalian cells by
transient transfection and purified by anion exchange chroma-
tography followed by size exclusion chromatography32, which
resulted in a distinct peak consistent with ~1.2 MDa particles
(Supplementary Fig. 1a). Negative-stain electron microscopy of
purified nanoparticles followed by reference-free 2D classification
and averaging revealed spherical particles with four to six visible
regularly-spaced protruding spikes depending on the projection,
consistent with the octahedral symmetry of the ferritin nano-
particle (Supplementary Fig. 1b). Cryo-electron microscopy
analysis further resolved the structures of these nanoparticles to a
resolution of 4.7–6.4 Å (Fig. 1c). All three nanoparticles were
homogeneous and contained a well-defined 12–13 nm diameter
ferritin core and clearly visible trimeric HA stem spikes with
heights of ~7 nm, demonstrating that neither the gN38, nor the
R38 modification affected the particle formation or trimerization
of HA stem spikes (Fig. 1c). To test whether the introduction of
the potential glycosylation site at 38HA1 resulted in glycosylation,
we performed SDS-PAGE analysis of the purified H1ssF variants.
While H1ssF WT and R38 resulted in approximately the same
mobility shift in the reduced SDS-PAGE, H1ssF gN38 migrated
higher than the other variants, indicating a larger molecular
weight for this construct. This difference in mobility shift was not
apparent when the proteins were treated with a deglycosydase
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PNGase F which removes glycans attached to Asn residues,
suggesting the presence of additional N-linked glycans in H1ssF
gN38 accounted for the observed difference in mobility shift
(Supplementary Fig. 1c). To test antigenicity of the stem nano-
particle variants, we used group 1-specific VH1-69-derived bNAbs
CR6261 (refs. 12,15) and 02-1H01 (ref. 40), murine group 1-
specific antibody C179 (ref. 41), cross-group reactive FI6v3
(ref. 10) and MEDI8852 (ref. 21) stem-directed bNAbs, and group
2-specific CR8020 (ref. 42). As expected, unmodified H1ssF (WT)
was recognized by group 1-specific CR6261, 02-1H01, C179 and
cross-group bNAbs similarly by ELISA (Fig. 1d). Analogous to
H1ssF WT, H1ssF R38 reacted with CR6261, FI6v3, and
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MEDI8852, but reactivity to 02-1H01 and C179 was lower than
the H1ssF WT. However, while retaining reactivity to cross-group
bNAbs, the reactivity of the H1ssF gN38 variant to group 1-
specific bNAbs was severely compromised (Fig. 1d). None of
these nanoparticles showed binding to either the group 2-specific
CR8020 or the anti-RSV D25 control antibody43. These results
confirm that introducing the group 2-like glycan at N38HA1 on
the group 1 HA stem nanoparticle alters antigenicity of group
1 stem by selectively limiting access of strictly group 1-specific
stem-directed antibodies.
Immunogenicity of H1 stem nanoparticle variants in mice. We
next sought to evaluate the impact of the modifications at posi-
tion 38HA1 on H1ssF on immunogenicity in vivo. Mice were
immunized three times with H1ssF WT, H1ssF gN38 or H1ssF
R38 formulated with Sigma Adjuvant System (SAS) at weeks 0, 4,
and 8. All the H1ssF variants elicited robust antibody responses to
the homologous A/New Caledonia/20/99 H1N1 (NC99) HA
(Fig. 2a, left) since these H1ssF variants shared most of the
solvent-exposed HA stem surface for immune recognition.
However, when we tested serum recognition of the NC99 HA
harboring the gN38 mutation (NC99 HA gN38; H38N/V40T in
HA1), the antibody titers in mice immunized with H1ssF gN38
and R38 were significantly higher than that of H1ssF WT-
immunized mice (p < 0.0001, and p= 0.0412, nonparametric
Kruskal–Wallis test with Dunn’s multiple comparisons, respec-
tively) (Fig. 2a, right). This indicated that both H1ssF gN38 and
R38 variants directed the antibody responses that were capable of
tolerating the glycan at position 38HA1. Interestingly, the pseu-
dovirus neutralization half-maximal inhibitory concentration
titers (IC50) to homotypic NC99 and H1N1 A/Singapore/6/86
(SG86) strains elicited by H1ssF WT were higher than the titers
elicited by the H1ssF gN38 and R38 variants (Fig. 2b). The
apparent inverse correlation between binding titers and neu-
tralization titers suggests that the majority of neutralizing anti-
bodies elicited by H1ssF WT were blocked by the gN38 mutation.
Moreover, H1ssF gN38 elicited significantly lower antibody
responses to heterosubtypic group 1 HA from H5N1 A/Vietnam/
Fig. 1 Design and characterization of group 1 H1 stem nanoparticle variants. a Comparison of N-linked glycosylation pattern of group 1 and group 2 HA
stem. Surface renderings of HA trimer for a representative group 1 HA (A/Solomon Islands/06 (H1N1), PDB: 3SM5, left) and representative group 2 HA
(A/Finland/486/04 (H3N2), PDB: 2YP5, right). One monomer is colored in blue for visibility. The terminal N-acetylglucosamine (GlcNAc) moiety for each
glycan is modeled in green and residue positions are labeled according to the H3 numbering. Yellow areas designate the approximate location of the
CR6261 epitope on each HA. b Amino acid sequence alignment of N-terminal portion of HA1 of H1 (A/New Caledonia/20/99), H3 (A/Finland/486/04)
and designed variants gN38 and R38. Dots and dashes indicate residues identical to H1 and gaps, respectively. c Cryo-electron microscopy structures of
H1 stem nanoparticle (H1ssF WT) and its variants H1ssF gN38 and H1ssF R38. Nanoparticles are depicted along the 2-fold symmetry axis. Side views of HA
stem trimeric spikes are shown below each nanoparticle. The maps were low-pass filtered to a resolution of 7 Å for comparison. Scale bar indicates 5 nm.
d Antigenicity of H1 stem nanoparticle variants. ELISA binding curves are shown for mAbs specific to group 1 stem (CR6261, 02-1H01 and C179), group
2 stem (CR8020), both group 1 and 2 stems (FI6v3, MEDI8852), or irrelevant RSV F protein (D25). Source data are provided as Source Data file.
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Fig. 2 Immunogenicity of H1 stem nanoparticle variants in mice. BALB/c mice (N= 10) were immunized with 2 µg of H1ssF WT, H1ssF gN38 or H1ssF
R38 on weeks 0, 4, and 8. Serum antibody titers to HAs were measured at 2 weeks after the third immunization (week 10). a ELISA endpoint titers to H1N1
NC99 HA (left) and its gN38 variant (right). b Serum neutralizing antibody titers to NC99, SG86, and CA09 (H1N1) pseudoviruses. Shown are half-
maximal inhibitory dilution of serum (IC50). c ELISA endpoint titers to H5N1 VN04 (left) and H7N9 AN13 HAs (right). d Serum neutralizing antibody titers
to H5N1 VN04 and H7N9 AN13 pseudoviruses. Dotted lines indicate the lower detection limit of the assay. Data are presented as scattered dot plots with
horizontal lines indicating geometric mean for each group. Statistical analysis was carried out by using nonparametric Kruskal–Wallis test with Dunn’s
multiple comparisons. Displayed results are representative of two independent experiments (H1ssF WT and H1ssF gN38) or based on one experiment
(H1ssF R38). Source data are provided as Source Data file.
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1203/04 (VN04) virus compared with that of H1ssF WT and
H1ssF R38 (p= 0.0003 and p= 0.0197, nonparametric
Kruskal–Wallis test with Dunn’s multiple comparisons, respec-
tively) (Fig. 2c, left). Similar results were observed when the
immune sera were tested for a different H5 HA (A/Indonesia/5/
05) (Supplementary Fig. 2a). These reduced H5-binding antibody
titers in mice immunized with H1ssF gN38 also resulted in a loss
of neutralizing activity against H5N1 VN04 pseudovirus (Fig. 2d,
left), suggesting that the gN38 mutation masked a major het-
erosubtypic neutralization-sensitive epitope(s). In contrast, mice
immunized with H1ssF gN38 generated substantially higher
antibody responses to heterosubtypic group 2 HA from H7N9 A/
Anhui/1/13 (AN13) virus than mice immunized with H1ssF WT
or H1ssF R38 (p < 0.0001 or p= 0.0412, nonparametric
Kruskal–Wallis test with Dunn’s multiple comparisons, respec-
tively) (Fig. 2c, right). Similarly, immune sera obtained from
H1ssF gN38-immunized mice had higher reactivity to another H7
HA (A/Shanghai/1/13) (Supplementary Fig. 2a). Furthermore,
considerable virus neutralization activity against H7N9 AN13
pseudovirus was also detected in immune sera obtained from
mice immunized with H1ssF gN38. However, no such activity
was found in sera from mice immunized with H1ssF WT (Fig. 2d,
right). Immunization with H1ssF R38 resulted in an intermediate
immunogenicity profile with lower H5N1 reactivity than H1ssF
WT and lower H7N9 reactivity than H1ssF gN38 (Fig. 2c, d and
Supplementary Fig. 2a). Therefore, H1ssF gN38 elicited antibody
responses that were distinct from that induced by H1ssF WT and
cross-reacted with distantly related group 2 H7N9 virus.
We also tested immune sera from mice immunized with group
2 H7 stem nanoparticle (H7ssF)40 as a comparator in the ELISA
against H7N9 AN13 HA. The serum H7-binding titers in H7ssF-
immunized mice were significantly higher than those in H1ssF
gN38-immunized mice by ~2 log10 (Supplementary Fig. 2b). This
suggests that although the glycan repositioning of H1ssF shifts the
antibody responses to be more cross-reactive with group 2 HAs,
the magnitude of the response is not comparable to that induced
by the genuine group 2 stem immunogen. It is important to note
however, that neither the glycan-unmodified group 1 nor the
group 2 stem immunogen elicits cross-group neutralizing anti-
body responses in mice.
Specificity of serum neutralizing activity. We next defined the
specificity of virus neutralizing antibodies in the immune sera
elicited by H1ssF WT, gN38, or R38 vaccination. To detect
whether the serum neutralizing activity was targeted to the site
around 38HA1, we performed neutralization assays in the presence
of excess amounts of either NC99 HA, NC99 HA gN38, or
an irrelevant RSV F protein (DS-Cav1)44 and assessed
non-competed neutralizing activity. Expectedly, most of the
neutralization activity was depleted when immune sera were pre-
incubated with NC99 HA WT and only negligible reduction in
neutralization was observed with DS-Cav1 in all immunization
groups (Fig. 3a). Although pre-incubation with NC99 HA gN38
had a minor impact (mean ± s.d. of 26.72 ± 7.16% inhibition) on
neutralization activity of immune sera obtained from mice
immunized with H1ssF WT, the same treatment resulted nearly
complete inhibition (80.38 ± 5.29%) in neutralization for immune
sera obtained from mice immunized with H1ssF gN38 (Fig. 3a,
b). Pre-incubation of immune sera obtained from mice immu-
nized with H1ssF R38 with NC99 HA gN38 resulted in a more
modest inhibition (72.97 ± 8.28%) in neutralization activity.
These results indicate while H1ssF WT induces substantial neu-
tralizing antibody titers targeting the site at or near position
38HA1, the majority of neutralizing antibodies elicited by H1ssF
gN38 and H1ssF R38 either targets site(s) outside of position
38HA1 or tolerate the glycan attached to this position. Moreover,
the strong competition of neutralizing activity in H1ssF g38-
immunized mice by NC99 HA WT (Fig. 3a) suggests that the
neutralizing epitope(s) do not require the N38 glycan for anti-
body recognition.
Homotypic, heterosubtypic, and cross-group protection. To
assess how changes in cross-reactivity of antibody responses
induced by H1ssF gN38 impact protective immunity, we carried
out experimental challenge studies with multiple influenza viruses
in mice. Mice were immunized three times with either H1ssF WT
or H1ssF gN38 with SAS adjuvant at weeks 0, 4, and 8, and
infected with either antigenically mismatched H1N1 A/Cali-
fornia/07/09 (CA09), heterosubtypic group 1 H5N1 VN04, or
heterosubtypic group 2 H7N9 AN13 virus between weeks 16 and
18. Both H1ssF WT and gN38 provided complete or near com-
plete protection against H1N1 CA09 virus (Fig. 4a, left) with very
mild weight loss compared with control animals (Fig. 4a, right).
Consistent with our previous results32, H1ssF WT immunization
conferred near complete protection against heterosubtypic group
1 H5N1 VN04 infection. However, H1ssF gN38 provided no
protection against the H5N1 virus (Fig. 4b, left) and immunized
mice suffered weight loss similar to that observed in naïve ani-
mals (Fig. 4b, right). This loss of heterosubtypic H5N1 protection
reflected severely diminished ELISA binding titers as well as
serum neutralization activity against the H5N1 virus (Fig. 2c, d).
Remarkably, mice immunized with H1ssF gN38 were partially
protected (45% survival) from heterosubtypic group 2 H7N9
AN13 virus infection in contrast to only 5–10% survival with
either H1ssF WT or mock immunized animals (Fig. 4c).
Although the survivors in the H1ssF gN38-immunized mice
appeared to lose substantial weight (−13.67 ± 3.65% at the peak)
upon H7N9 infection and the protection was not optimal, this
improved cross-group protection provided by the H1ssF gN38
was statistically significant when compared with mice immunized
with H1ssF WT or naïve control (p= 0.019 or p= 0.0003,
Mantel-Cox log-rank test with Bonferroni correction, respec-
tively) (Fig. 4c). These results suggest that even a modest increase
in serum antibody cross-reactivity to group 2 heterosubtypic
H7N9 virus induced by H1ssF gN38 can result in improved cross-
group protective efficacy against the group 2 H7N9 virus in
immunized mice.
Cross-group protection by hyperimmune immunoglobulins.
To further characterize the cross-group reactivity of serum anti-
bodies elicited by H1ssF gN38 immunization, we affinity-purified
Igs from immune sera by using recombinant H7N9 AN13 HA.
The purified H7N9 AN13 HA-reactive Igs not only bound
H7N9 AN13 HA but also HAs derived from other group 2 sub-
types H10N8 A/Jiangxi-Donghu/346/13 (JD13) and H3N2
A/Hong Kong/1/68 (HK68) viruses, albeit with weaker affinity
than to H7N9 AN13 HA (Fig. 5a). Importantly, the H7N9 AN13
HA-reactive Igs also recognized autologous NC99 HA as they
were elicited by H1ssF gN38 immunization, though reactivity to
H5N1 IN05 HA was negligible (Fig. 5a). Neutralizing activity of
the affinity-purified Igs for H7N9 AN13 and H3N2 HK68
pseudoviruses reached an IC50 concentrations of 2.12 and 18.08
µg ml−1, respectively, but neutralizing activity against H5N1
VN04 pseudovirus was undetectable (>50 µg ml−1) (Fig. 5b). To
assess whether the H7N9 AN13 HA-reactive Igs provide pro-
tection when prophylactically administered into naïve animals,
we passively immunized mice with 0.2 mg of Igs (~10 mg kg−1)
24 h prior to infection with H7N9 AN13 virus. Following the
virus infection, mice that received H7N9 AN13 HA-reactive Igs
or control influenza bNAb FI6v3 (~5 mg kg−1) did not suffer
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substantial weight loss and survived 100% throughout the study
period (Fig. 5c). In contrast, 9 out of 10 mice that received
control naïve Igs lost substantial weight and had to be euthanized
by 7 days post infection (Fig. 5c). Collectively these results indi-
cate that H1ssF gN38 is capable of eliciting antibodies that cross-
react with multiple group 2 subtype HAs and when these group 2
HA-reactive antibodies are given prophylactically to naïve ani-
mals they confer complete cross-group protection against other-
wise lethal H7N9 virus infection.
Discussion
Despite immense efforts to curtail influenza infections over the
past several decades and the availability of licensed commercial
vaccines, seasonal influenza remains a major public health burden
worldwide. Furthermore, there are many other exotic virus sub-
types in animal reservoirs that pose potential human pandemic
threats. Sporadic outbreaks of animal influenza viruses such as
H5N1, and H7N9 further accentuate the need for developing
broadly protective countermeasures that are effective beyond
seasonal influenza viruses to protect the public from a potentially
serious pandemic. Universal influenza vaccines that elicit protec-
tive immunity across all potential subtypes and lineages of viruses
would be an ideal solution to achieve this goal. The discovery in
1993 of the murine antibody C179 that targets the conserved HA
stem and neutralizes multiple subtypes within group 1 influenza A
viruses41 and the subsequent discovery of multiple human bNAbs
targeting the same stem region10–15,20,45–48 have revealed the
vulnerabilities of the HA stem supersite, making it a prime target
for universal influenza vaccines5,22–25,49,50. Although HA stem-
directed bNAbs can serve as a basis for universal influenza
immunity, many published bNAbs are specific to or preferentially
recognize HAs within either group 1 or group 2. Only a handful of
bNAbs are capable of crossing the group boundary, suggesting a
substantial bottleneck to eliciting cross-group antibody reactivity
even in individuals with repeated influenza exposures. One major
obstacle to overcoming the group boundary is the difference in
glycosylations between group 1 and group 2 stems which differ-
entially regulate accessibility of antibodies to the underlying
epitopes22,35. Most of group 1 HAs possess an N-linked glycan at
N33HA1, whereas this glycosylation site is shifted to N38HA1 in
most group 2 HAs. These group-specific glycans appear to serve as
gatekeepers by allowing or disallowing stem-directed B cells (and
eventually antibodies) to approach, and hence shaping the anti-
body responses specifically toward one group over the other.
Indeed, the introduction of the group 2-like glycosylation at
N38HA1 in an H5 HA was observed to diminish binding of a
canonical group 1-specific bNAb CR6261 by ~70%15. We have
shown that introduction of this glycan blocks binding of group
1-specific antibodies but not cross-group antibodies. Substituting
the position 38HA1 residue with Arg results in only a marginal
reduction in recognition of group 1-specific antibodies, indica-
ting that the bulky glycan moieties are needed to more fully
block the access of these antibodies. Importantly, the mutual
exclusivity or strong group favoritism of the HA stem-directed
antibodies applies also to vaccines as neither group 1- nor group
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2-based HA stem immunogens convincingly elicit protective
antibody responses that overcome the group boundary in ani-
mal models32–34,40. Similarly, a natural Ile to Phe variation
observed in human H2 HA at the position 45HA2 which resides in
close proximity to 38HA1 makes it more resistant to many HA
stem-specific monoclonal antibodies (mAbs) than other group
1 subtype HAs22,49. In the present study, we have demonstrated
that by simply changing the glycosylation pattern on the stem can
alter the group-specificity of vaccine-elicited antibody responses in
mice. Although the gN38 variant induced cross-group protective
antibody responses, the glycan modification also resulted in the
complete loss of group 1 heterosubtypic protection from H5N1.
We speculated that the majority of H5-reactive serum antibody in
H1ssF WT-immunized mice was targeted by a site immediately
adjacent to the position 38HA1. Although the modifications to
position 38HA1 limited access of B cells targeting this adjacent site,
the degree of inhibition appeared size dependent, with the larger
gN38 modification creating more steric occlusion than the R38
modification. While the gN38/R38 modifications inhibit the access
of H1/H5 cross-reactive B cells, the obstruction redirects antibody
responses to a slightly shifted site which appears to be conserved
between H1 and group 2 HAs, but not H5. To optimally achieve
both cross-group and intra-group heterosubtypic protection, fur-
ther studies are needed to fine tune the stringency of the glycan-
mediated blockage on the group 1 HA stem-based immunogen.
For example, partially trimming the glycans to reduce the bulki-
ness of the gN38, altering the position of the N38 glycan,
assembling heterotypic HA stem variants like wild-type and gN38
on the same nanoparticle, or engrafting the group 1 stem residues
onto the group 2 stem backbone with its natural glycan at N38HA1,
may further broaden the antibody immune response.
In humans, the group 1 stem-directed antibody responses are
largely dominated by a single VH gene family, VH1-69
(refs. 14,15,22,38,51–53), both in the context of natural exposure to
pandemic H1N1 infection in 2009–2010 (refs. 36,51) as well as
vaccination with a non-circulating group 1 HA22. The unique
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hydrophobic properties of the CDR H2 encoded in most VH1-69
alleles has an inherent affinity to the Trp21HA2 pocket on the HA
stem surrounded by residues including 38HA1 and 45HA2 which
results in this heavy chain being overrepresented in antibodies
elicited to this site36,51. However, this particular hydrophobic CDR
H2 motif (Ile53 and Phe54) is not present in any known VH genes
from other species, including mice. Interestingly, the first stem-
directed murine antibody C179 (ref. 41) interacts with the Trp21
pocket on the stem in a remarkably similar way as VH1-69 anti-
bodies but by utilizing its CDR H3 loop54. This suggests that mice
can also generate these kinds of antibodies although it is not as
reproducible as the human germline-encoded VH1-69 response.
While several murine and other animal species have been engi-
neered to carry partial or entire human immunoglobulin loci to
produce humanized antibodies, recapitulating the VH gene-
dependent immune responses in these animal models is still
challenging55–59. Moreover, cross-group bNAbs often have
human-specific immunogenetic constraints that could be even
more difficult to recapitulate in animal models22,35,49,60.
Although these and other caveats such as differences in the clonal
deletion process, V gene usage in naïve repertoire or VDJ
recombination need to be considered, in principle these ‘huma-
nized’ animals could still be very helpful models to test VH-
restricted responses.
Another important aspect of human influenza immunology to
consider is the preexisting immunity established through either
natural exposures and/or vaccinations. The complexity and
individualized history of influenza exposure is impossible to
replicate in current animal models. It is important to note that the
vast majority of preclinical studies are performed in antigen-naïve
animals. Immunological imprinting from early-life exposures has
also been implicated to have a substantial impact on skewing
subsequent immune response to influenza virus potentially for
life61,62. Therefore, for influenza-naïve individuals, the order of
initial antigen exposures may be more important than antigen-
experienced individuals to establish influenza virus-specific B cell
repertoire with desired specificity. Current vaccines deliver mul-
tiple influenza strains in a single formulation with the intent of
maximizing the breadth of HA-directed protective antibody
responses in adults with preexisting immunity. This may not be
ideal for naïve individuals in whom the goal is to establish specific
broadly cross-reactive lineages. Such lineage-targeting may be
better accomplished by a narrowed set of antigens. For antigen-
experienced adults, the exotic non-circulating group 2 immuno-
gen (i.e., H7N9 split vaccine) could preferentially boost antibody
responses with greater cross-group reactivity potential by avoid-
ing dominant group 1-specific VH1-69 lineage antibodies37,38,49.
Our findings in the present study suggest that the gN38 variant of
the group 1 stem nanoparticle would not only mitigate the eli-
citation of group 1-specific antibodies, but also completely avoid
boosting of head-directed, strain-specific antibody responses.
This group 2-like immunogen complements our earlier devel-
opment of group 1 HA stem nanoparticle, which confers intra-
group heterosubtypic protection in mice and ferrets32, and group
2 HA stem nanoparticles, which confer homotypic protection in
mice40. These stem immunogens could potentially be used in a
heterologous prime-boost regimen to focus antibody responses to
the cross-group HA stem supersite. They could also be given
together in a manner analogous to the current multivalent inac-
tivated influenza vaccines (IIV) or in combination with IIV to
mitigate the inevitable risk of discordance between vaccine and
circulating strains.
Together, our study shows the importance of a group-
determining stem glycan on dictating the specificity of vaccine-
elicited stem-directed antibody responses and offers insights on
design options for more universal influenza vaccines.
Methods
Expression and purification of immunogens and antibodies. All HA nanoparticles
were expressed in Expi293 cells (ThermoFisher Scientific) and purified by ion
exchange chromatography using a HiTrap Q HP column (GE Healthcare). Briefly,
cleared transfection supernatants were diluted three times with Tris-HCl (pH 8.0)
buffer at a final concentration of 50mM Tris-HCl, ~50mM NaCl. Diluted super-
natants were directly loaded on an anion exchange column (HiTrap Q HP) and
captured nanoparticles were eluted with a linear gradient NaCl (50–300mM) in
50mM Tris-HCl (pH 8.0) buffer. Fractions containing H1ssF (H1ssF) based on
A/New Caledonia/20/99 (NC99) nanoparticles were concentrated and further purified
by size exclusion chromatography with a Superose 6 pg XK 16/70 column (GE
Healthcare) and the purity of the materials were assessed by SDS-PAGE and blue
staining (SimplyBlue SafeStain, ThermoFisher Scientific). HA trimers, DS-Cav1 tri-
mers, and FI6v3, CR8020, CR6261, C179, 02-1H01 and MEDI8852 mAbs were also
expressed in Expi293 cells and purified by Ni-NTA (HA) or Ni-NTA and Strep-Tactin
(DS-Cav1) followed by size exclusion chromatography, or by protein A (mAbs). All
proteins and mAbs were tested for antigenicity and specificity prior to use.
Negative-stain electron microscopy. H1ssF nanoparticle samples were diluted to
~20 µg ml−1 with a buffer containing 10 mM HEPES (pH 7.0) and 150 mM NaCl.
Nanoparticles were adsorbed to a freshly glow-discharged carbon-film grid for 15 s,
washed with the above buffer, and stained with 0.75% uranyl formate. Micrographs
were collected using the EPU software on a ThermoFisher Scientific Talos F200C
electron microscope operated at 200 kV using a 4k × 4k Ceta CCD camera (pixel
size of 2.5 Å). Particles were selected from the micrographs automatically using in-
house written software (Y.T., unpublished) and subjected to reference-free 2D
classification in Relion63.
Cryogenic electron microscopy and structure determination. H1ssF nano-
particles at a concentration of ~1 mgml−1 were vitrified at room temperature and
90% humidity using Vitrobot Mark IV (FEI) by applying a 2.7 µl drop to a glow-
discharged holey carbon grid (Quantifoil R 1.2/1.3, gold support), blotting for 2 s,
and plunging into liquid ethane cooled by liquid nitrogen. Datasets were collected
using a Talos F200C electron microscope (ThermoFisher Scientific) operated at
200 kV and equipped with a side-entry cryo-holder (Gatan 626). Movies containing
40 frames each were recorded using a Falcon 3EC direct electron detector in the
integrating mode at a nominal magnification of 92,000× corresponding to a pixel
size of 1.58 Å. The frame exposure time was 50 ms (total movie exposure time: 2 s),
and the total dose was 60 e/A2. The defocus range was 1.5–4 µm underfocus. A
total of 118, 248, and 106 movies were recorded for the H1ssF WT, H1ssF gN38,
and H1ssF R38, respectively. Motion correction was performed using MotionCor2
(ref. 64). Ctffind 4.1 was used to estimate the defocus of motion-corrected micro-
graphs65. The resulting micrographs and the ctffind output were examined, and
low-quality images were excluded from further processing. Approximately 2000
particles were picked manually for each nanoparticle from these micrographs and
subjected to 2D classification in Relion 2.1 (ref. 63). Selected resulting classes were
low-pass filtered and used as templates for automatic particle selection as imple-
mented in Relion. Particles were extracted into 180 × 180-pixel (H1ssF WT, H1ssF
gN38) or 200 × 200-pixel (H1ssF R38) boxes. The resulting particle stacks con-
tained 66,602, 168,964, and 68,863 particles, respectively, for H1ssF WT, H1ssF
gN38, and H1ssF R38. The particles were subjected to two rounds of 2D classifi-
cation with selection of best-looking classes. Initial three-dimensional models were
obtained from these classes in EMAN2 (ref. 66). Model refinement was performed
in Relion 2.1 with octahedral symmetry imposed, which was followed by three-
dimensional classification. The best-looking 3D class was selected, and the
refinement was repeated. A total of 51,586, 33,531, and 13,539 particles contributed
to the final cryo-EM map of H1ssF WT, H1ssF gN38, and H1ssF R38, respectively.
The 3D maps were sharpened by applying a negative B-factor (−500 Å2 for H1ssF
WT, −300 Å2 for H1ssF gN38, −200 Å2 for H1ssF R38) during post processing.
The resolutions determined according to the gold-standard approach using a
Fourier shell correlation threshold of 0.143 were 6.3 Å (H1ssF WT), 4.7 Å (H1ssF
gN38), and 6.4 Å (H1ssF R38). Local resolution was estimated in Relion. The
strongest EM density, which corresponded to the highest resolution, was observed
in the ferritin core. HA stem spikes were observed at lower map thresholds, and the
resolution in these areas was lower due to higher flexibility. Figures were prepared
using UCSF Chimera67.
ELISA. ELISA was used to measure binding of H1ssF WT, H1ssF gN38, and H1ssF
R38 nanoparticles to mAbs CR6261, CR8020, MEDI8552, FI6v3, C179, 02-1H01,
and D25 (anti-RSV). 96-well plates were coated with 2 μg ml−1 H1ssF WT, H1ssF
gN38, and H1ssF R38 (0.1 ml per well) and incubated at 4 °C overnight. For testing
HA-specific IgG levels in immune sera, plates were coated with 2 μg ml−1 of
recombinant HA proteins derived from H1 NC99 WT, H1 NC99 gN38, H5 IN05,
and H7 SH13. Plates were then blocked with PBS containing 5% skim milk at 37 °C
for 1 h. Monoclonal antibodies and immune sera were serially diluted in four-fold
steps and added to the wells for an hour. Horseradish peroxidase (HRP)-con-
jugated anti-human or anti-mouse IgG (Southern Biotech) was added and incu-
bated at 37 °C for 1 h. The wells were developed with 3,3′,5′,5-tetramethylbenzidine
(TMB) substrate (KPL), and the reactions were stopped by adding 1M H2SO4
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before measuring absorbance at 450 nm with a Spectramax Paradigm plate reader
(Molecular Devices).
Animal experiments. All animal experiments were reviewed and approved by the
Institutional Animal Care and Use Committee of the VRC, NIAID, NIH. All
animals were housed and cared for in accordance with local, state, federal, and
institutional policies of NIH and American Association for Accreditation of
Laboratory Animal Care.
Immunization and challenge studies. BALB/cJ mice (Jackson Laboratory) were
immunized intramuscularly (IM) with 2 μg of H1ssF WT, H1ssF gN38 and H1ssF
R38 with Sigma Adjuvant System (SAS) on weeks 0, 4, and 8 (N= 10). Mice were
given 50 μl into each hind leg. Serum samples were collected before and after each
immunization and tested for the immunogenicity by ELISA and pseudovirus-
neutralization assays. For the challenge studies, mice infected with 10–20 times
50% lethal dose (LD50) of H1N1 A/California/07/09, H5N1 A/Vietnam/1203/04 or
H7N9 A/Anhui/1/13 virus intranasally at Bioqual. The animals were monitored
twice daily for development of clinical signs and weighed daily for 14 days. Any
animals that had lost 20% or more of their initial body weight were euthanized.
Pseudovirus-neutralization assays. Pseudovirus-neutralization assays were carried
out using luciferase encoding lentiviruses pseudotyped with influenza HA and
NA68,69. HA and NA sequences used to generate pseudoviruses were derived from A/
New Caledonia/20/99 (H1N1), A/Singapore/6/86 (H1N1), A/California/4/09 (H1N1),
A/Vietnam/1203/04 (H5N1), A/Anhui/1/13 (H7N9), and A/Hong Kong/1/68
(H3N2). 293T cells were cotransfected with pCMV-ΔR8.2 (lentiviral backbone) and
pHR’-CMV-Luc (reporter genome) plasmids along with plasmids encoding desired
HA and corresponding NA, and human transmembrane serine protease 2
(TMPRSS2) by the calcium-phosphate method (Promega). After overnight incuba-
tion, wells were washed, and replenished with fresh medium. Forty eight hours later,
supernatants were harvested, filtered through a 0.45 µm, aliquoted, and frozen at
−80 °C until use. Each pseudovirus stock was titrated prior to use in neutralization
assays. Mouse sera were treated with receptor destroying enzyme (RDE (II); SEIKEN
Accurate Chemical and Scientific) and heat-inactivated before subjecting to the assays.
Immune sera or monoclonal antibodies were serially diluted and incubated with pre-
titrated HA-NA pseudotyped viruses for 30min at room temperature. Serum-
pseudovirus mixture was then transferred to 96-well white/black isoplates (Perki-
nElmer), and 12,000 293 A cells were added into each sample well of the plate. After
overnight incubation at 37 °C, wells were supplemented with 100 μl of fresh Dul-
becco’s modified Eagle medium including 5% fetal bovine serum (Fisher Scientific),
and 5000 units ml−1 penicillin-streptomycin (Gibco), and the plates were incubated in
a static 37 °C, 5% CO2, humidified incubator for 48 h. Cells were lysed with cell
culture lysis buffer (Promega) and luciferase activity in the lysate was measured using
Luciferase kit (Promega). Luminescence was measured with a Spectramax L lumin-
ometer (Molecular Devices). For neutralization competition assays, mouse immune
sera were pre-incubated with NC99 WT HA, gN38 HA, or control RSV F protein (at
a final concentration of 50 µgml−1) at RT for 1 h prior to perform the pseudovirus-
neutralization assays described above. Serum dilution or antibody concentration that
gives 50% neutralization (IC50) values were calculated from neutralization curves
(four-parameter nonlinear regression model) and plotted with GraphPad Prism 8.
Purification of polyclonal Ig. To generate hyperimmune Ig, 100 female BALB/cJ
mice (6–8 weeks old; Jackson Laboratory) were immunized three times with H1ssF
gN38 protein (2 μg per immunization with SAS) at weeks 0, 4, and 8 and sera were
collected at 1 and 2 weeks after the last immunization prior to terminal bleed at
3 weeks after the last immunization. Briefly, 10 mg H7 AN13 HA protein was
immobilized on NHS-Activated Agarose Dry Resin (Thermo Scientific) for 2 h at
RT. After coupling, the resin was washed three times with PBS, then pooled
immune sera was added. The column was incubated overnight at 4 °C. After
washing the column briefly, captured antibodies were eluted with low-pH IgG
elution buffer (Thermo Scientific) and the eluates containing H7-specific antibodies
were immediately neutralized by adding 1 M Tris-HCl (pH 8.0) at a final con-
centration of 100 mM. Purified H7-specific antibodies were dialyzed two times
against PBS, concentrated to ~1.0 mgml−1 and stored in −80 °C until use.
Passive transfer studies. BALB/cAnNHsd mice (Envigo) were given a 0.1 mg of
FI6v3 (~5 mg kg−1) or 0.2 mg of purified H7-specific or control naïve Igs (~10 mg
kg−1) intraperitoneally (N= 10). Twenty-four hours later, the mice were infected
intranasally with 10 × LD50 of H7N9 A/Anhui/01/2013 (H7N9) at Bioqual. The
animals were monitored twice daily for development of clinical signs and weighed
daily for 14 days. Any animals that had lost 20% or more of their initial body
weight were euthanized.
Statistical significance. All statistical analysis was performed using Prism 7 or 8
(GraphPad software). Sample sizes of animals and specific tests to determine sta-
tistical significance used are indicated in the methods and corresponding figure
legends. P values < 0.05 were considered statistically significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data generated or analyzed during this study are included in this published article and
available in a Source Data file. The source data underlying Figs. 1d, 2a–d, 3a, b, 4a–c, and
5a–c, and Supplementary Figs. 1a, and 2a, b, and uncropped gel image of Supplementary
Fig. 1c are provided as a Source Data file. The H1ssF constructs used in this study have
been deposited in the NCBI GenBank under accession numbers MN585111–MN585113.
The Cryo-EM maps described in this study have been deposited in the EM Data Bank
(EMDB) under accession numbers EMD-20911–EMD-20913.
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